Megablockbuster day for Roche too as MS game-changer Ocrevus gets a green light at the FDA
Tuesday turned out to be the day for a game of megablockbusters. Regeneron and Sanofi snagged an FDA OK for Dupixent, a landmark new eczema therapy, and now Roche came through with a thumbs up for ocrelizumab, which promises to remap the landscape for the multiple sclerosis drug market.
Ocrelizumab — which will now be sold as Ocrevus — could be used to treat most MS patients, a combination of relapsing/remitting and primary progressive patients. That’s a unique distinction that is likely to make this a key focus among doctors who specialize in treating MS. And that could be a game change for everyone in the field.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.